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The congenital muscular dystrophies comprise a genetically and clinically heterogeneous group of disorders characterized by early onset of
progressive muscle weakness and often involvement of other organ systems such as the brain and eyes. During the last decade, significant progress
has been made to further characterize various forms of congenital muscular dystrophies based on their specific genetic and clinical appearance.
This review represents an overview of the recent accomplishments as they relate to clinical, diagnostic, pathogenetic and therapeutic aspects of
congenital muscular dystrophies.
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Congenital muscular dystrophy (CMD) was first described in
1903 by Frederick Batten [1], for a more detailed historical
overview see Tome and Voit [2]. Given the recent improvement
of molecular technologies, the classification of CMD's has
significantly changed from phenotype driven towards a more
molecular based categorization (see Table 1). So far up to eleven
genes are known to cause various forms of CMD and several
clinically distinct entities of CMD's which are not linked to any
of the described forms emphasize that the number of causativeAbbreviations: MDC1A, congenital muscular dystrophy type 1A; LAMA2,
laminin-α2 gene; DGC, dystrophin–glycoprotein complex; MDC1D, congenital
muscular dystrophy type 1D; FKRP, fukutin-related protein; MDC1C,
congenital muscular dystrophy type 1C; LGMD2I, limb-girdle muscular
dystrophy type 2I; FCMD, Fukuyama congenital muscular dystrophy;
POMGnT1, O-linked mannose β1,2-N-acetylglucosaminyl-transferase; MEB,
muscle–eye–brain disease; POMT1, protein O-mannosyltransferase I; WWS,
Walker–Warburg syndrome; UCMD, Ullrich congenital muscular dystrophy;
RSMD1, rigid-spine muscular dystrophy; SEPN1, selenoprotein N; ITGA7,
alpha7 integrin gene
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[3,4].
2. MDC1A and laminin-α2
MDC1A is an autosomal recessive form of congenital
muscular dystrophy caused by deficiency in laminin-α2 [5,6].
Laminins are heterotrimers consisting of an α, β, and γ subunit,
and variants of each combine to form tissue and developmen-
tally specific isoforms. Laminin-α2 is encoded by the LAMA2
gene (6q22–q23), and is the α subunit of laminin-2 which is
also referred to as merosin [7,8]. Various mutations in the
LAMA2 gene have been found to cause a deficiency in merosin,
either in quantity or function [5,9].
Laminin-α is comprised of the α2, β1, and γ1 subunits
(Fig. 1a), and is found at the basement membrane of striated
muscle, placental trophoblast cells, and peripheral nerve
Schwann cells [10–12]. Myotendinous junctions and neuro-
muscular junctions represent two major sites of expression for
laminin-α2, although it is widespread throughout the basal
lamina [7]. Laminin-4 (α2, β2, γ1) is a prevalent laminin that
differs from merosin by the replacement of the β1 subunit with
a β2. This isoform is expressed in a developmentally regulated
Table 1
Congenital muscular dystrophies associated with genetic causes
Disease Gene
symbol
Protein Clinical features
Merosin deficient
CMD (MDC1A)
LAMA2 laminin-α2 Muscular dystrophy, respiratory insufficiency and nocturnal hypoventilation, white matter changes, neuronal
migration abnormalities and mental retardation (rare) seizures, peripheral neuropathy, CK elevated
MDC1B linked to
1q42?
? Facial weakness, diaphragmatic involvement with early respiratory failure, rigid spine, secondary laminin α2
deficiency
Rigid spine syndrome
(RSMD1)
SEPN1 selenoprotein-1 Muscular dystrophy, axial hypotonia and weakness, lumbar scoliosis and cervical spine stiffness, respiratory
failure due to skeletal abnormalities and diaphragmatic weakness, CK normal or mildly elevated
Integrin a7 congenital
myopathy
ITGA7 integrin α7 Mild muscular dystrophy/myopathy, mental retardation, torticollis, mildly elevated CK
Ullrich's disease
(1,2,3)
COL 6A1
COL 6A2
COL 6A3
collagen VI Neonatal muscle weakness, kyphosis of spine, joint contractures, torticollis, hip dislocation, hyperextensibility
of distal joints, follicular hyperkeratosis, cheloid formation, invariable respiratory insufficiency, normal
intelligence, CK normal or mildly elevated,
MDC1D LARGE LARGE Muscular dystrophy, profound mental retardation, subtle brain abnormalities
Walker–Warburg
syndrome
POMT1
POMT2
POMT1
POMT2
Muscular dystrophy, type II lissencephaly/agyria, hydrocephalus, eye abnormalities, life expectancy <3 years,
CK elevated
Muscle–eye–brain
disease
POMGnT1 POMGnT1 Muscular dystrophy, broad clinical phenotype, significant hypotonia, eye abnormalities and abnormal neuronal
migration
Fukuyama CMD FKTN Fukutin Muscular dystrophy, severe brain involvement with mental retardation, cardiomyopathy, seizures, eye
abnormalities
MDC1C FKRP Fukutin-related
protein
Muscular dystrophy, congenital weakness and hypotonia, calf and tounge hypertrophy, shoulder muscle
wasting, cardiomyopathy, severe end of the spectrum: structural brain changes, retinal changes with blindness,
CK elevated
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synapse. The limited synaptic expression of β2 in adulthood
drives this pattern of regionalization [13]. Laminin-α2 is also
present at basal lamina of neural vasculature, although it is not
expressed in the vasculature of other tissues [14].
Laminins have a variety of functional roles. In almost every
tissue type laminins form an essential structural element of the
basement membrane. They bind at the cell surface to both
dystroglycan and integrin where they serve as part of the
structural scaffold and as an active signaling cascade modifying
cell differentiation, tissue survival and composition [7]. The
binding of laminin-α2 to α-dystroglycan depends on the
proteolytic cleavage of laminin into 300 kDa and 80 kDa
segments, and without this cleavage binding is reduced by as
much as 10 fold [15]. The relationship between laminin and its
binding partners appears to be more complex than a simple
physical tether. Dystroglycan and integrins are critical for the
polymerization of laminin-α2, and the ultrastructural organiza-
tion of the receptors is dependent on laminin [16]. Laminin-α2
has additional functions in the brain that are not fully understood.
This is supported by the white matter changes evident in patients
with a deficiency of laminin-α2 [7] (see below).
2.1. Clinical manifestations and diagnosis
Patients with MDC1A suffer from a variety of symptoms
beginning in infancy or early childhood including hypotonia,
kyphoscoliosis, and joint contractures. Patients have delayed
motor milestones and often do not achieve ambulation.
Respiratory insufficiency is a common manifestation that may
progress to the requirement of supportive ventilation. Serum
creatine kinase levels are markedly elevated by as much as 150
times above the normal level [3,17,18].The brain is affected in numerous ways with notable
variation in severity. Normal intelligence is found in a majority
of patients, although some present with seizures and mental
retardation [18]. After 6 months of life, most MDC1A patients
have a specific pattern of white matter changes on brain MRI
with increased signal intensity on T2-weighted images [4]. In
addition, patients show signs of dysmyelinating motor neuro-
pathy with reduced nerve conduction velocity [4]. Cerebellar
hypoplasia has been observed in patients with and without
intellectual involvement [19]. In some cases autopsy and MRI
revealed occipital agyria and polymicrogyria, a clear display of
the extreme variation in phenotype [20,21]. Cardiac failure
seems to be a rare feature of this disorder [22], although
echocardiographic evidence of left ventricular hypokinesia has
been observed [23]. Visual function is however affected,
abnormal responses of visual and somatosensory evoked
potentials [24] and partial external ophthalmoplegia with
limited ocular movements have been reported [25].
Diagnosis of MDC1A is made by muscle biopsy and
molecular genetic testing. Skeletal muscle abnormalities include
dystrophic changes such as muscle fiber necrosis, with signs of
ongoing degeneration and regeneration. Often, a significant
increase in endomysial connective tissue around muscle fibers
is present indicating end-stage muscle disease. Immunohisto-
chemical studies focus on the expression pattern of the C-and N-
terminal form of laminin-α2. A subset of patients show absence
and/or marked reduction in the C-terminal 80 kDa cleavage
product of laminin-α2 while others display only a reduction in
the N-terminal 300 kDa portion [26,27]. Patients with preserved
C-terminal expression and reduced N-terminal expression of
laminin-α2 exhibit a milder phenotype [26]. Therefore,
antibodies directed against the C-and N-terminal portion of
laminin-α2 must be used to accurately assess a particular
Fig. 1. (a) Overview of the proteins associated with congenital muscular dystrophies. Highlighted proteins are known to cause various forms of congenital muscular
dystrophies. ER, endoplasmic reticulum. (b) Overview of proteins involved in the glycosylation of α-dystroglycan. Abbreviations see text; ER, endoplasmic reticulum.
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reduced at the sarcolemma of laminin-α2 deficient tissues
making it an effective secondary marker [28]. Other secondary
protein abnormalities include integrin α7 which is reduced at
the sarcolemma as well as laminin-α4 and α5 which display an
increased sarcolemmal expression pattern [29–31]. Skin biopsy
can be an assistive diagnostic tool as laminin-α2 is reduced at
the dermal epidermal junction in cases of MDC1A [32].
Prenatal diagnosis is available by chorionic villus sampling
(CVS) in families with a child previously diagnosed with
MDC1A [33–36]. Absent laminin chains, normally expressed
in the basal lamina of trophoblasts and intramesodermal blood
vessels, indicate MDC1A in the fetus [36]. Reduced laminin-α2
could be the secondary result of another gene defect, and this
emphasizes the need for molecular studies in conjunction with
CVS for accurate diagnosis [33,34,37].
Recently an autosomal recessive form of congenital
muscular dystrophy, characterized by proximal weakness,
generalized muscle hypertrophy, rigidity of the spine, and
contractures of the Achilles tendon, was described in a
consanguineous family from the United Arab Emirates. Earlyrespiratory failure resulting from severe diaphragmatic involve-
ment was present. Serum creatine kinase levels were grossly
elevated, and muscle-biopsy samples showed dystrophic
changes with secondary laminin-α2 deficiency. This disorder
however was linked to chromosome 1q42 [38].
2.2. Pathogenesis and genetics
The Gene LAMA2 encodes for laminin-α2 and is located at
loci 6q22–q23 [11]. Complete laminin-α2 deficiency is
responsible for almost half of all cases of CMD and follows a
recessive pattern of inheritance. Not all cases of laminin-α2
deficiency can be associated with definitive causative mutations
in LAMA2, although the majority of patients with clinical
manifestations show some change in the LAMA2 sequence that
represents putative mutations [39]. Mutations in LAMA2 can
cause partial or complete deficiency in laminin-α2, with most
mutations causing the latter [40]. Severity of phenotype is highly
dependent on the type of mutation with complete absence of
protein leading to severe, early-onset phenotype, and partial
deficiency leading to variable expression of disease [41,42] (Fig.
Fig. 2. Expression of laminin-α2 in CMD. Complete absence of the C-terminal portion of laminin-α2 is associated with a more severe phenotype, while partial
deficiency of laminin-α2 leads to a milder phenotype.
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laminin-α2 with its binding partners cause more severe
phenotypes even if the protein is detectable in tissues [15].
Recent developments of animal models and patient studies
have greatly advanced the understanding of disease mechanisms
involved with MDC1A. The current animal models available to
study are the dy and dy2j mice (natural occurring mouse models
with absent and reduced laminin-α2 expression) and the
genetically engineeredmodels dyWand dy3K [43–46]. In patients
with MDC1A and in the dy/dy mice, structural alterations of the
basal lamina have been observed [47]. The integral structural
organization of the basal lamina is crucial to the function of
skeletal muscle, and the observed derangement would have
expected implications on the growth, maintenance and force
development in skeletal muscle. In dy/dy2Jmice, the distribution
of laminin, dystroglycan and dystrophin were abnormal and not
costameric. This represents a structural abnormality directly
affecting the force generating capacity of the muscle and a
possible explanation for the generalized muscle weakness [8].
The altered basal lamina morphology in Schwann cells is a
possible cause of the slowed peripheral nerve conduction, and a
likely contribution to the sequelae of this disease.
2.3. Therapy and future perspectives
Currently, there is no course of treatment that deals directly
with laminin-α2 deficiency in MDC1A patients, although
possible treatments have been investigated. Expression of
laminin-α2 in dyW and dy2J mice (both partly deficient) causes
some degree of rescue in the muscle phenotype with improved
longevity and muscle morphology [48]. Overexpression of
agrin in laminin-α2 deficient mice has been shown to reduce the
disease effects in muscle tissue by stabilizing α-dystroglycan
which normally binds laminin [49–51]. Other molecular routes
have been shown to benefit the phenotype of laminin-α2
deficient mice. Transgenic overexpression of laminin-α1 proves
to be beneficial to the skeletal muscle and infertility phenotype
of laminin-α2 deficient mice [52,53]. Various studies demon-
strated that increased apoptosis plays a role in the pathogenesis
of laminin-α2 deficient muscular dystrophy [31]. Inhibition of
apoptosis has consequently been shown to ameliorate the
skeletal muscle phenotype in Lama2-null mice [54,55]. Recent
work investigated the mechanism by which the extraocular
muscle (EOM) is spared from disease effects in dy mice.Upregulation of laminin-α4 in EOM subsequent to laminin-α2
deficiency is thought to provide a protective function by binding
integrins [56]. The possibility of laminin-α4 as a protective
agent opens up yet another avenue of research in the search for
novel and effective therapeutic interventions.
2.4. Dystroglycanopathies (congenital disorders of
O-glycosylation)
Within the last few years an increasing number of genes
encoding for putative or demonstrated glycosyltransferases
have been associated with various forms of autosomal
recessive congenital muscular dystrophies often associated
with structural eye and brain changes [57–59]. Six of these
genes (POMT1, POMT2; POMGnT1; FKRP; Fukutin;
LARGE) encode for proteins involved in the glycosylation of
α-dystroglycan (Fig. 1b). Abnormal glycosylation of this
molecule is a common finding in all the respective conditions
(Walker–Warburg syndrome; Muscle–Eye–Brain disease;
congenital muscular dystrophy type 1C; Fukuyama congenital
muscular dystrophy and congenital muscular dystrophy type
1D). Despite that the defect of abnormal glycosylated
dystroglycan expression appears to be secondary, its critical
involvement in the pathogenesis of these muscular dystrophies
led to the term dystroglycanopathies.
Dystroglycan is essential for basement membrane formation
[60]. Generation of dystroglycan-null mice leads to embryonic
lethality due to failure of basement (Reichert's) membrane
formation that separates the embryo from the maternal
circulation [61]. Generation of chimeric and skeletal muscle
specific dystroglycan null mice (MCK-null) demonstrate loss of
the dystrophin–glycoprotein complex with subsequent devel-
opment of muscular dystrophy [62,63]. Interestingly,MCK-null
mice do not develop progressive muscular dystrophy due to
preserved dystroglycan expression in satellite cells and
subsequent efficient muscle regeneration indicating that main-
tenance of effective muscle regeneration represents a key
mechanism in the pathogenesis of muscular dystrophies [62].
Dystroglycan is encoded by the DAG1 gene and undergoes
posttranslational modification to yield two glycoproteins known
as α-and β-dystroglycan [64]. Dystroglycan was originally
isolated from skeletal muscle as an integralmembrane component
of the dystrophin–glycoprotein complex (DGC) [65]. At the
sarcolemma β-dystroglycan binds intracellularly to dystrophin,
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dystroglycan. α-Dystroglycan, a highly glycosylated peripheral
membrane protein, completes the link from the cytoskeleton to
the basal lamina by binding to extracellular matrix proteins
containing LamG domains, such as laminin [66], neurexin [67],
agrin [68,69], and perlecan [15]. Dystroglycan undergoes N-
linked and extensive O-linked glycosylation, and as a result α-
dystroglycan migrates on SDS-PAGE as a broad band with an
approximate molecular mass of 120–180 kDa, depending on
tissue type (156 kDa in muscle, predicted molecular mass is
∼75 kDa) [70]. The perturbation of the synthesis of O-
mannosyl tetrasaccharide (a fairly rare modification in mam-
mals) leads to hypoglycosylation ofα-dystroglycan and abolishes
ligand-binding activity [64], [71]. It is believed that hypoglyco-
sylation of α-dystroglycan and subsequent perturbation of
dystroglycan binding to its ligand partners, in particular to
laminin, leads to disruption of the critical link between the
cytoskeleton and extracellular matrix in skeletal muscle. During
the last few years it has become clear that hypoglysylation of α-
dystroglycan plays a crucial role in various forms of muscular
dystrophies. Moreover, the severity of the phenotype and the
degree of organ involvement can vary significantly (see below). It
should be emphasized that immunohistochemical staining for the
glycosylated form of α-dystroglycan serves as a straightforward
tool in the diagnostic muscle biopsy workup of dystroglycano-
pathies irrespective of the specific gene mutation. The following
paragraphs represent an overview of the different forms of
muscular dystrophies caused by abnormal glycosylation of α-
dystroglycan.
3. Congenital muscular dystrophy type 1D (MDC1D)
The identification of altered glycosylation of α-dystrogly-
can due to a loss-of-function mutation of a putative
glycosyltransferase named Large in the myodystrophy mouse
model (Largemyd) was the first demonstration that abnormal
glycosylation can cause a neuromuscular disorder [71,72]. The
Large gene encodes a putative glycosyltransferase with a
transmembrane domain followed by a coiled-coil domain and
two DxD-containing catalytic domains [58]. The Largemyd
mouse develops muscular dystrophy, abnormal gait and
posture and decreased reproductive fitness, cardiomyopathy,
sensorineural hearing loss, neuronal migration defects and
abnormal retinal transmission [71,73]. Longman and collea-
gues [74] recently identified a heterozygous mutation G1525A
(Glu509Lys) in exon 13 and a heterozygous 1 bp insertion,
1999insT in exon 15 in the LARGE gene in a 17 year-old girl.
The patient presented with congenital onset of weakness
(around 5 months of age), profound mental retardation and an
abnormal electroretinogram with significant alteration of the b-
wave response. MRI of the brain revealed white matter
changes and subtle structural abnormalities indicative of
abnormal neuronal migration [74]. The skeletal muscle biopsy
of this patient showed severe muscular dystrophy with reduced
expression of glycosylated α-dystroglycan, and biochemical
analysis revealed decreased molecular weight of α-dystrogly-
can and impaired laminin-binding activity.LARGE exhibits important functions in skeletal muscle.
Kanagawa et al. [75] demonstrated that molecular recognition
by LARGE is essential in the biosynthetic pathway for a mature
and functional dystroglycan [75] as post-translational modifica-
tion of α-dystroglycan by LARGE occurs within the mucin-like
domain. Biochemical evidence revealed that interaction of
LARGE with the N-terminal domain of α-dystroglycan
represents an intracellular enzyme recognition motif which is
required to initiate efficient glycosylation. These data indicate
that disruption of the dystroglycan-laminin linkage caused by
absence of the critical glycosylation/LARGE recognition
represents an essential mechanistic pathway ultimately leading
to skeletal muscle cell necrosis and degeneration in muscular
dystrophy [75]. There are currently no specific therapeutic
alternatives available, however, Barresi et al. [76] showed that
overexpression of LARGE in Largemyd mice induced synthesis
of glycan-enriched α-dystroglycan accompanied by high
affinity for extracellular ligands subsequently ameliorating the
dystrophic pathology in these mice. Moreover, the authors
demonstrated that overexpression of LARGE is able to bypass
glycosylation defects in other forms of muscular dystrophies
caused by abnormal glycosylation of dystroglycan. These data
emphasize that manipulation of endogenous LARGE expres-
sion and activity represents a promising future therapeutic target
for various muscular dystrophy syndromes caused by abnormal
glycosylation of α-dystroglycan.
4. Walker–Warburg syndrome
Walker–Warburg syndrome (WWS) is the most severe
amongst the dystroglycanopathies, with most patients dying by
age of 3 years [77]. It is characterized by severe congenital
muscular dystrophy, ocular abnormalities (such as retinal
detachment and malformations, cataracts, microphthalmia,
anterior and posterior chamber malformations, optic nerve
hypoplasia, coloboma, glaucoma), and structural brain abnorm-
alities (type II lissencephaly or cobblestone lissencephaly,
agenesis of the corpus callosum, cerebellar hypoplasia,
hydrocephalus and rarely encephalocele) [78]. The pathological
changes in the central nervous system are thought to be
secondary to pial glial limitans defects which resemble the
morphological findings observed in mice with a tissue specific
deletion of dystroglycan in brain [79].
Belran-Valero de Bernabe et al. [80] identified mutations in
the gene encoding protein O-mannosyltransferase I (POMT1)
in 6 out of 30 unrelated cases with WWS suggesting genetic
heterogeneity. Subsequent to the discovery of the initial disease
causing mutations various other forms of congenital muscular
dystrophies have been associated with mutations in POMT1.
The expanding phenotype of patients with POMT1 mutations
includes microcephaly, calf hypertrophy [81] and patients who
do not exhibit signs of ocular and brain malformations [82].
Moreover, mutations in POMT2, which together with POMT1
is required to achieve protein O-mannosyltransferase activity,
has been demonstrated in patients with classic WWS [83].
POMT1, which belongs to the family of protein mannosyl-
transferases has three transmembrane segments in the C-
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differs markedly from the other glycosyltransferases and
putative transferases and therefore might function outside of
the Golgi apparatus. POMT1 and POMT2 are both ER-resident
glycosyltransferases which act as a complex in catalyzing the
O-mannosylation of α-dystroglycan [83].
Profound depletion of α-dystroglycan and defective
glycosylation of α-dystroglycan causing loss of laminin-
binding activity in skeletal muscle and peripheral nerve can
be observed in patients with POMT1 mutations [80,84–86].
5. Muscle–eye–brain disease
Muscle–eye–brain disease (MEB) is an autosomal recessive
disorder characterized by congenital muscular dystrophy, ocular
abnormalities (congenital myopia, glaucoma and retinal hypo-
plasia), mental retardation and structural brain malformations
(pachygyria, cerebellar hypoplasia and flat brain stem) [87].
Most of the patients so far have been described in a genetically
isolated population, the Finns [77] although mutations have
now been described throughout the world [88]. Yoshida et al.
[89] identified a mutation in the gene that encodes O-linked
mannose β1,2-N-acetylglucosaminyl-transferase (POMGnT1),
a type II membrane protein similar to other Golgi glycosyl-
transferases. Mutations of the POMGnT1 gene comprise the
first biochemical evidence that congenital muscular dystrophies
associated with loss of α-dystroglycan expression are indeed a
defect of protein glycosylation, and enzyme activity of
POMGnT1 has been found to be significantly reduced [89].
Hypoglycosylation of α-dystroglycan in skeletal muscle is
associated with abolished ligand binding activity of laminin,
agrin and neurexin [71]. Mutations in the POMGnT1 gene have
also been identified in patients outside of Finland [90], namely
in Japan and Korea. Interestingly, genetic analyses revealed that
patients with milder clinical cases most often exhibit a mutation
located towards the 3′ end of the POMGnT1 gene, while
patients with a more severe phenotype tend to have mutations
toward the 5′ end of the gene [90].
Various groups have tried to develop enzymatic assays to
diagnose POMGnT1 related conditions. Zhang et al. [91] used
an enzymatic assay with commercially available reagents and
demonstrated decreased POMGnT1 activity in skeletal muscle
biopsies of four patients with POMGnT1 mutations. Vajsar et al.
[92], have recently reported a new fibroblast and lymphoblast
based protein O-mannosyl beta-1,2-N-acetylglucosaminyltrans-
ferase 1 enzymatic assay, which allows rapid and accurate
diagnosis of carriers and patients with muscle–eye–brain type
of congenital muscular dystrophy. Genetic engineering of mice
lacking POMGnT1 reproduces the phenotype observed in
patients and will be of benefit in studying further aspects of the
molecular pathogenesis and the development of therapeutic
strategies [93].
6. Fukuyama congenital muscular dystrophy
Fukuyama type congenital muscular dystrophy (FCMD) is
an autosomal recessive disorder that is most often seen inJapanese populations [94]. In Japan, its incidence is roughly 1
per 10,000 births, a frequency equivalent for Duchenne
muscular dystrophy in the worldwide population. FCMD is
characterized by severe congenital muscular dystrophy,
cardiomyopathy, neuronal migration abnormalities associated
with mental retardation and epilepsy, and frequently eye
abnormalities (such as optic atrophy and retinal detachment)
[94,95]. Most Japanese patients with the disease carry an
ancestral 3 kB retrotransposonal insertion in the 3′ noncoding
region of the FCMD gene [96], causing near absence of
fukutin mRNA in lymphoblastic cells isolated from FCMD
patients.
A broad correlation between genotype and phenotype in
FCMD patients has been recognized. It appears that patients
who are homozygous for the initially described ancestral
mutation have a rather milder phenotype, while disease severity
(associated eye abnormalities such as retinal detachment and
microphthalmos) increases in patients who are compound
heterozygous for the ancestral mutation and a more severe
loss-of-function mutation [97]. Interestingly, in contrast to fu-
kutin-null mice which are not viable, homozygous null
mutations in the FCMD gene have recently been characterized
in two patients of Turkish origin, suggesting that human life is
compatible with a homozygous null mutation [98]. These
patients presented with a more severe, WWS-like phenotype
than the general FCMD patient population and had a substantial
depletion of α-dystroglycan as shown by immunofluorescence.
This was the first case of a fukutin mutation found outside the
Japanese population.
Fukutin, the product of the FCMD gene, has sequence
similarities to several putative glycosyltransferases and has an
Asp–Xaa–Asp motif in its C-terminus. This motif is conserved
in many families of glycosyltransferases and is essential for
enzymatic activity [99]. Hayashi et al. [100], demonstrated that
α-dystroglycan and laminin α2 expression were reduced in
FCMD patient's skeletal and cardiac muscle. Generation of
chimeric mice for fukutin demonstrated muscular dystrophy
with reduced survival rate, and a significant disorganization of
the laminar structures of the cerebral and cerebellar cortices and
the hippocampus [101]. These mice also exhibited defects in
lens development and retinal detachment, as well as cortical
neuronal over-migration and defects of the interhemispheric
fissure. Biochemical analysis of these mice revealed decreased
expression of glycosylated α-dystroglycan and disrupted
laminin ligand activity. Further analyses of human and mouse
models are needed to dissect the functional role of fukutin in
muscle and nerve tissues.
7. Congenital Muscular Dystrophy Type 1C (MDC1C)
MDC1C is characterized by mutations in the fukutin-related
protein gene (FKRP) was initially characterized based upon its
sequence homology with fukutin [102]. Mutations in the FKRP
gene can be detected in a very broad patient population. The two
distinct phenotypes can be categorized into congenital muscular
dystrophy type 1C (MDC1C) and limb girdle muscular
dystrophy type 2I (LGMD 2I) (for review see[57–59]). The
Fig. 3. Loss of glycosylated α-dystroglycan in a patient with a mutation in the FKRP gene. Note that in this patient, expression of laminin-α2 is not affected.
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the MDC1C category generally present with severe muscle
weakness early in life and usually do not achieve ambulation.
Recent reports of patients with FKRP mutations exhibit
evidence of cerebellar abnormalities, lissencephaly, pachygyria
and brain stem hypoplasia [103,104]. Immunohistochemical
studies of α-dystroglycan in skeletal muscle of MDC1C muscle
suggest a correlation of α-dystroglycan expression and disease
severity [105]. Patients with MDC1C and a phenotype at the
severe end of the disease spectrum showed profound depletion
of α-dystroglycan expression (Fig. 3). In contrast, patients with
LGMD2I and a milder phenotype have more variable and subtle
alterations in α-dystroglycan labeling [105].
Patients with MDC1C often are compound heterozygous for
either one missense and one nonsense or two missense
mutations, while patients with two nonsense mutations have
not yet been described [106]. Another evidence of clinical and
molecular heterogeneity has come from reports of novel
missense mutations in the FKRP gene which causes marked
phenotypic variability within the same family [107,108]. These
observations suggest that genetic modifiers and/or environ-
mental factors play a role in modulating disease severity in
MDC1C and LGMD2I.
FKRP, a type II transmembrane protein, is ubiquitously
expressed in all tissues. It contains a DxD motif suggestive of a
glycosyltransferase. In vitro localization studies have shown a
subcellular localization within the Golgi apparatus and disease
causing mutations lead to endoplasmic reticulum retention of
the mutated protein [109,110]. Interestingly, overexpression in
Chinese hamster ovary cells revealed that FKRP directly affects
dystroglycan processing, a phenomenon completely abolished
in case of a mutated FKRP [109,110].
8. Ullrich congenital muscular dystrophy (UCMD)
UCMD (MIM #254090) is an autosomal recessive disorder
which has been initially characterized by its clinical manifesta-tions of generalized hypotonia and contractures [111]. UCMD,
as well as the phenotypically less severe Bethlem Myopathy,
results from a deficiency in the extracellular matrix protein
Collagen VI [3]. Collagen VI comprises the α1, α2, and α3
peptide chains which are encoded by the corresponding genes
COL6A1, COL6A2, and COL6A3. Mutations in COL6A1 and
COL6A2 (located at 21q22), and COL6A3 (at 2q37) cause
UCMD, and both recessive and dominant patterns are observed
as modes of inheritance [112–115]. Collagen VI is a
microfibrillar component found throughout the extracellular
matrix of fibroblasts and the connective tissue of skin, large
vessels, as well as skeletal, smooth and cardiac muscle
[116,117]. Its prevalence in the reticular layer of the basement
membrane, and its binding to fibronectin and collagen type IV
[43], indicates a structural role in muscle fibers. The lost
connection between the basal lamina and interstitium, as a result
of deficient collagen VI, has been implicated in the pathogen-
esis associated with UCMD [118]. Collagen VI has also been
shown to induce proliferation of fibroblasts [119], drive gene
expression, enhance tyrosine kinase activity [120], and inhibits
Bax activation consequently reducing cellular apoptosis events
[121]. The disruption of these functions represents potential
components of UCMD pathogenesis and provides direction for
the discovery of therapeutic measures.
8.1. Clinical manifestations and diagnosis
Patients with UCMD present in the neonatal period with
hypotonia, distal joint laxity, and proximal contractures. Hip
dislocation and torticollis are common features evident during
the first year of life along with scoliosis, severe respiratory
impairment, spinal rigidity, and failure to thrive [122]. Severity
of clinical features is highly variable and closely linked to the
degree of collagen deficiency [123]. For example, a subset of
patients achieves ambulation and suffers a relatively mild
motor deficiency while others have severely impaired motor
function and development. Respiratory complications can
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contractures can worsen over time often requiring surgical
intervention. Hyperhidrosis of the skin, facial weakness with
high arch palate, and prominent ears are common features of
patients with UCMD [3]. Creatine kinase levels are normal or
within five times the normal level, and mental development is
unaffected [3]. Diagnosis requires muscle biopsy with
immunohistochemical analysis of collagen VI in tissue and
cultured fibroblasts and gene testing. Histological abnormal-
ities of skeletal muscle in UCMD include variation in fiber
size, muscle fiber necrosis and increased connective tissue in
the endomysium and perimysium. Immunohistochemical
staining can reveal a variety of patterns ranging from complete
absence in some patients, to partial reduction in others, and
some cases with no apparent reduction in collagen VI level
[118,122]. Other samples have been identified where collagen
VI fails to localize to the basement membrane surrounding the
muscle fiber causing a mild form of UCMD [114]. Collagen VI
may also fail to form the normal network structure in the
extracellular matrix due to truncated or absent α chains [124].
Muscle MRI has also been proposed as a diagnostic tool,
specifically when collagen VI expression is normal in skeletal
muscle and/or skin [125]. Patients with UCMD show diffuse
patches of abnormal signal in the thigh muscles and display the
pattern regardless of the level of collagen expression [125]. The
genetic heterogeneity of this disorder introduces difficulties in
molecular testing. Only a portion of the known cases have
either collagen VI deficiency or mutations in the genes coding
for collagen VI α chains, but mutations in each of the three
genes have been characterized and could potentially be used for
genetic testing. Prenatal diagnosis, through CVS, is possible in
families where an affected child displays UCMD with collagen
VI deficiency and a distinguishable genotype. Brockington et
al. [126], have recently reported haplotype analysis of markers
on COL6A3, in conjunction with immunohistochemical
collagen VI labeling as a measure to diagnose UCMD in a
fetus.
8.2. Pathogenesis and genetics
Upon discovery of the first mutations in the collagen VI
genes, it was established that UCMD displayed recessive
inheritance through homozygous or compound heterozygous
mutations. Patients can present with recessive mutations in both
COL6A2 and COL6A3 that caused a deficiency in collagen VI
and the UCMD phenotype [112–115]. Dominant mutations in
the same COL6A genes are associated with the less severe
Bethlem Myopathy. Later it was discovered that a heterozygous
deletion in COL6A1 is responsible for the more severe UCMD
phenotype [114]. This exposed the first dominant inheritance
pattern for UCMD, blurring the lines between Bethlem
Myopathy and UCMD, and introducing new molecular
mechanisms for the disorder [127]. Recently 79 Patients with
Bethlem Myopathy and UCMD had all three COL6A genes
sequenced and examined. Many new mutations were discov-
ered with 62% of patients showing possible mutations in at least
one COL6A gene [128]. The severity of the disease followsclosely with the level of collagen VI deficiency [123], but loss
of collagen VI may affect the level of disease through several
mechanisms. EM images of a patient with complete collagen VI
deficiency displayed the absence of microfibrils thereby
disrupting the link between the basal lamina and the
interstitium. The loss of this connection has been implicated
as a possible mechanism for the reduced structural integrity of
muscle fibers in these patients [118]. EM also revealed changes
in the ultrastructure of skin biopsies. Collagen fibrils showed
variation in size and ground substance, findings that are also
features of connective tissue disorders such as Ehlers–Danlos
syndromes [129]. Experiments with collagen VI deficient mice
have enhanced our understanding of other possible pathome-
chanisms in UCMD [130]. Muscle fibers in these mice showed
alterations in sacrcoplasmic reticular ultrastructure associated
with mitochondrial dysfunction and increased apoptosis. The
observed ultrastuctural and physiologic changes caused a
measurable loss of contractile strength. Administration of
cyclosporine A reduced the apoptotic events and led to
preservation of structural integrity of skeletal muscle fibers
[131]. A recent study by Usuki et al. [132] demonstrated yet
another possibility for pathogenetic mechanism and therapeutic
intervention. The authors described that nonsense mediated
decay (NMD) may be responsible for some of the collagen
mutations in patients with UCMD. They were able to show that
siRNA-mediated knockdown of SMG-1 or Upf1 (both essential
proteins of NMD) led to up-regulation of the mutant triple-
helical collagen VI, resulting in the formation of partially
functional extracellular matrix.
8.3. Therapy and future perspectives
Currently there is no direct treatment for deficiency of
Collagen VI, but therapeutic intervention to prevent the
sequelae of UCMD is important for the ongoing health and
quality of life of the patients. Contractures, respiratory failure,
scoliosis, and recurrent infections are common, and measures
such as early mobilization, surgical correction, respiratory
assistance, and early or preventative treatment of infections are
required to provide patients with maximum health, mobility and
functionality [128].
9. RSMD1 and selenocysteine
Rigid spine muscular dystrophy or RSMD1 is a rare form of
autosomal recessive congenital muscular dystrophy caused by
mutations in the SEPN1 gene [133–135]. The SEPN1 gene
encodes for selenoprotein N which is a selenium containing
glycoprotein located within the endoplasmic reticulum [135].
Selenium is added to the peptide chain in the form of a single
selenocysteine residue by a distinctly recognized stop codon.
Several other selenoproteins have been characterized, many of
which are enzymes involved in oxidation–reduction reactions,
and all of which have selenocysteine at their active site. Full-
length SEPN1 transcripts are expressed in a variety of tissues
including skeletal muscle, brain, and lung. It is also found in
the placenta and is more prevalent in fetal tissue than adult
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caused by mutations in the selenoprotein N has been
broadened. Ferreiro et al. [136], demonstrated mutations in
the SEPN1 gene in patients with classical presentation of multi-
minicore disease. In addition, desmin-related myopathy with
Mallory body-like inclusions is caused by mutations in the
SEPN1 gene [137].
9.1. Clinical manifestations and diagnosis
RSMD1 presents in the neonatal period with contractures of
the spinal extensors leading to rigidity of spine and thoracic
cage, facial and neck weakness, and hypotonia predominately
found in the axial musculature [138]. In infancy, patients
develop thoracolumbar scoliosis and diaphragmatic weakness
often requiring ventilation. Delay of gross motor milestones is
evident, although ambulation is eventually achieved and
preserved in most patients. Due to palatal weakness, nasal
speech is common. Patients exhibit failure to thrive with muscle
wasting. Patients do not exhibit mental retardation and have
normal brain MRIs. Muscular hypertrophy and contractures are
not associated with this condition, and serum creatine kinase is
close to or within the normal range.
Skeletal muscle biopsies show non-specific myopathic
changes such as fiber diameter variability, prevalence of type
1 fibers, atrophy and internalization of nuclei. Some
specimens contain minicores typical of classical minicore
myopathies [136]. Antibodies directed against the 70-kDa
SEPN1 can show absence of the protein in fibroblasts of
patients with nonsense mutations. Screening for mutations in
the SEPN1 gene is required to establish the diagnosis of
RSMD1.
9.2. Pathogenesis and genetics
Identification of selenoproteins as a cause for muscular
dystrophies is highly novel, therefore little is known about the
function of these proteins in skeletal muscle. Okamoto et al.
[139], recently described two new SEPN1 mutations in two
Japanese patients with RSMD1. Immunohistochemical studies
in these patients showed a reduced and irregular expression of
selenoprotein N and calnexin, a transmembrane protein of the
endoplasmic reticulum. One of the families studied showed a
homozygous 20-base duplication mutation at 80 (80_99dup,
frameshift at R27) which should lead to significant nonsense-
mediated decay (NMD). Unexpectedly, the authors detected a
truncated selenoprotein N suggesting that SEPN1 mRNAs
may be resistant to NMD. Further evaluation of NMD and
other potential pathways in this disorder is needed to shed
more light into the mechanism of selenoprotein related muscle
diseases.
9.3. Therapy and future perspectives
Possible therapies have been elusive due to the unique nature
of RSMD1. Unlike other congenital muscular dystrophies it
does not affect the basal lamina or laminin receptors. Novelpathways will need to be explored as further work helps define
the nature of this disease and its pathology.
10. α7 Integrin
The α7β1 integrin is a laminin receptor found on the surface
of myocytes forming an important connection between the cell
surface and basal lamina. Both α and β subunits are expressed
in tissue-specific variants formed by differential splicing in a
developmentally dependent manner [140,141]. The α7A and
α7β variants are expressed to a large extent in skeletal muscle,
specifically the myotendinous junctions, neuromuscular junc-
tions, and the sarcolemma, although it is also found in cardiac
and smooth muscle [142,143]. Alpha7B integrin binds laminin
within the plasma membrane forming an important support of
structural and functional stability within the skeletal muscle
[26,31]. The α7β1 integrin also functions to mediate migration
and proliferation of myoblasts [140]. More recently, the
functional understanding of α7β1 has been extended to the
development and maintenance of vascular smooth muscle
[144]. The discovery of the ITGA7 gene at locus 12q13 and the
subsequent generation of a homozygous knockout mouse
model were key steps in the determination of functional
deficiencies created in the absence of α7 integrin [143,145].
Among these were clear changes in skeletal muscle indicative
of muscular dystrophy, findings that were echoed later in
patients with congenital myopathy and reduced expression of
α7 integrin [MIM 600536, [146]].
10.1. Clinical manifestations and diagnosis
Three patients have been characterized with a deficiency in
α7 integrin leading to an autosomal recessive form of
congenital myopathy [146]. One patient showed significant
developmental delay characterized by mental retardation and
impaired achievement of motor milestones. There was also a
subtle increase in serum creatine kinase. A second patient was
observed to have similar motor delay, although eventually
achieved ambulation at 2 years of age. This patient was not
found to have mental involvement, but surgery was required to
repair torticollis and hip dislocation at 2 months of age, and
creatine kinase levels were found to be mildly elevated. A third
patient displayed torticollis and hypotonia, but had no apparent
mental involvement [146].
10.2. Pathogenesis and genetics
Two of the patients were compound heterozygous for
mutated alleles in the ITGA7 gene. Both patients had an allele
containing a 98-bp deletion, but the complimentary alleles were
unique in both cases. The third patient had a reduction in ITGA7
mRNA with no observed mutation in the ITGA7 gene.
Congenital myopathy and deficiency of α7 integrin is evident
in all of these patients by immunocytochemical techniques.
They are differentiated by the normal expression of laminin-α2,
and at least one patient has shown variable fiber size and
adipose infiltration [146].
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Currently there are no treatments available that can restore
the level of functioning α7β1, however, the potential for
replacing α7 integrin in other forms of muscular dystrophy have
recently been investigated. It was found that mice lacking
dystrophin and utrophin had lower prevalence of muscle
disease, better mobility, and longer lives when bred with mice
overexpressing α7β1 integrin [147]. Integrin α7β1 and the
dystroglycan complex are the major laminin receptors in the
myocyte membrane, and the expression of α7β1 is observed to
maintain the integrity of the myotendinous and neuromuscular
junction normally lost in dystrophin/utrophin deficient mice
[147,148]. These findings are supported by demonstration that
lack of α7 integrin and dystrophin exacerbates the dystrophic
disease process of dystrophin-deficient mdx mice [149].
11. Conclusion
The last century of research in the field of congenital
muscular dystrophies has led to exciting new discoveries
regarding the pathogenesis of these disorders. It has not only
significantly enhanced our understanding of the pathogenesis
of skeletal muscle pathology but shed light into the mechan-
isms of neuronal migration defects. For many years congenital
muscular dystrophies were thought to be a group of disorders
linked to abnormalities and perturbation of the extracellular
matrix. The identification of mutations encoding for seleno-
proteins in rigid spine syndrome which are enzymes located in
the endoplasmic reticulum, has led to a completely new
avenues of research in the pathogenesis of congenital muscular
dystrophies and potentially other muscle disorders. Further
characterization of the existing pathways and their potential
interaction with each other as well as identification of novel
clinical and molecular entities will expand our current knowl-
edge and serve as the basis for the development of future
therapeutic strategies. Among various options, these may
potentially involve enzymatic modifications of the glycosyla-
tion process of α-dystroglycan as well as modification of the
oxidation–reduction reactions involving selenoproteins.
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